ISTA Pharmaceuticals

Source: Wikipedia, the free encyclopedia.
ISTA Pharmaceuticals, Inc.
Websitewww.istavision.com

ISTA Pharmaceuticals, Inc, was a US-based

Valeant Pharmaceuticals withdrew its $360 million offer.[4]

Products

Litigation

On May 24, 2013, ISTA Pharmaceuticals entered a guilty plea to federal felony charge of conspiracy to introduce a misbranded drug into interstate commerce and conspiracy to pay illegal remuneration in violation of the Federal Anti-Kickback Statute. ISTA agreed to pay $33.5 million to resolve criminal and civil liability arising from its marketing, distribution and sale of its drug Xibrom.[9]

References

  1. ^ "ISTA: Profile for ISTA Pharmaceuticals, Inc. - Yahoo! Finance". Finance.yahoo.com. Retrieved October 28, 2009.
  2. ^ Lattman, Peter (26 March 2012). "Bausch & Lomb to Buy ISTA Pharmaceuticals for $500 Million". DealBook. Retrieved January 29, 2019.
  3. ^ Lattman, Peter (2012-03-26). "Bausch & Lomb to Buy ISTA Pharmaceuticals for $500 Million". DealBook. Retrieved 2019-10-21.
  4. ^ Scott, Mark (4 September 2012). "Valeant Sticks to Torrid Pace of Deal-Making". DealBook. Retrieved January 29, 2019.
  5. ^ "BROMDAY™ | Products". Archived from the original on 2011-07-13. Retrieved March 21, 2011.
  6. ^ "Relief from Allergic Conjunctivitis - BEPREVE : Bausch + Lomb". www.Bausch.com. Retrieved January 29, 2019.
  7. ^ "Bausch Consumer > en > ecp > our-products". www.Bausch.com. Retrieved January 29, 2019.
  8. ^ "Bausch Consumer > en > ecp > our-products". www.Bausch.com. Retrieved January 29, 2019.
  9. ^ "ISTA Pharmaceuticals Inc. Pleads Guilty to Federal Felony Charges; Will Pay $33.5 Million to Resolve Criminal Liability and False Claims Act Allegations". www.Justice.gov. May 24, 2013. Retrieved January 29, 2019.

External links